共 24 条
[1]
Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Reid T, Warren R, Kirn D. Cancer Gene Therapy . 2002
[2]
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53（INGN201）and radiation therapy. Swisher SG, Roth JA, Komaki R, et al. Clinical Cancer Research . 2003
[3]
p53 gene therapy for esophageal cancer. Shimada H,Matsubara H,Ochiai T. Journal of Gastroenterology . 2002
[4]
Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Martin B, Bradly GW. Cancer Research . 1999
[5]
Phase2breastcancerstudyshowsclinicalresponsesin90percentofpatientstreatedwithIntrogen′sAdvexintherapy. . 2003
[6]
Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Frank DK, Frederick MJ, Liu TJ, et al. Clinical Cancer Research . 1998
[7]
Clinical update of Ad-p53 gene therapy for lung cancer. Swisher S G, Roth J A. Surgical Oncology Clinics of North America . 2002
[8]
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. Pagliaro LC, Keyhani A, Williams D, et al. Journal of Clinical Oncology . 2003
[9]
Introgen′sIntrabronchialAdvexintherapydemonstratessafetyandclinicalactivityinbronchoalveolarlungcancer. . 2003
[10]
p53 gene therapy: a key to modulating resistance to anticancer therapies. Chang EH, Pirollo KF, Bouker KB, et al. Molecular Medicine Today . 2000